Trasylol

Trasylol (aprotinin) is a drug that was used during complex surgeries, primarily heart surgery, to minimize bleeding. It was supposed to make surgeries safer and reduce the need for blood transfusions, but turned out to have deadly side effects. Bayer, maker of Trasylol, stopped marketing the drug in November, 2007, and began removing the medication from warehouses, hospitals, and doctor’s supplies in May, 2008. Trasylol is no longer available in the U.S.

Trasylol Dangers

Several studies have found that heart surgery patients were more likely to die when Trasylol was used during surgery. An American study found a 78% greater risk of death one week after surgery. A Canadian trail was halted before completion because the death rate with Trasylol use was so much high.

Trasylol can cause:

  • Kidney failure
  • Heart attack
  • Heart failure
  • Stroke

Of course, Trasylol can cause more than one of these adverse events in the same patient. Often a chain reaction ensues, leading to death. Many who experience Trasylol kidney failure require dialysis treatments and still go into multi-organ failure.

Trasylol death can happen shortly after the initial surgery using the drug, or after months of severe health problems, surgeries, and other medical treatments administered in an attempt to save the patient’s life. In short, Trasylol death can be a long and excruciating process for Trasylol victims and their loved ones.

Bayer and the FDA Could Have Prevented Thousands of Deaths

In 2006, a U.S. Food and Drug Administration (FDA) advisory committee met to consider the dangers of Trasylol and whether the drug should be allowed to remain in use. A study by Dr. Dennis Mangano, which showed that the drug did increase the risk of kidney failure and death, was presented to the committee.

At the time of the meeting, Bayer had results from its independent study, which showed similar results, but it withheld the information from the FDA. The agency decided to keep Trasylol on the market.

A week after the decision, the author of Bayer’s study alerted the FDA to the results of the study and the fact that Bayer had kept it a secret, but the agency still did not request a recall of the deadly drug.

Dr. Mangano calculates that 22,000 lives could have been saved if the FDA had pulled Trasylol when it had the chance after his study rather than waiting until two years later.

If you or a loved one has been harmed by Trasylol or died from Trasylol injuries, you may be entitled to compensation. A Trasylol injury attorney in your area can help. Please schedule a consultation to learn more right away.